Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder
Status:
Not yet recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Post-traumatic stress disorder (PTSD) is a complex disorder expressed as a variety of
neurobiological symptoms, including anxiety, re-experiencing, hyperarousal, and avoidance
symptoms, along with comorbidities such as anxiety, depression, and increased risk for
self-medicating substance abuse. Currently, there are only two approved medications in the
United States (US) for PTSD, paroxetine and sertraline.
Psychedelic medications, including psilocybin, have recently received breakthrough
designation by the US Food and Drug Administration (FDA) for other psychiatric indications.
Although no formal clinical trials have yet investigated psychedelic substances for the
treatment of PTSD, the available evidence warrants such an investigation. The present study
aims to investigate the effect of psilocybin on treatment-resistant PTSD.